Glycopyrrolate; Indacaterol Maleate Patent Expiration

Glycopyrrolate; Indacaterol Maleate was first introduced by Novartis Pharmaceuticals Corp in its drug Utibron Neohaler on Oct 29, 2015.


Glycopyrrolate; Indacaterol Maleate Patents

Given below is the list of patents protecting Glycopyrrolate; Indacaterol Maleate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Utibron Neohaler US8182838 Dry powder composition comprising co-jet milled particles for pulmonary inhalation Oct 20, 2028 Novartis
Utibron Neohaler US8479730 Inhaler device Oct 11, 2028 Novartis
Utibron Neohaler US6878721 Beta2-adrenoceptor agonists Feb 25, 2025

(Expired)

Novartis
Utibron Neohaler US7736670 Method of making particles for use in a pharmaceutical composition Jun 27, 2021

(Expired)

Novartis
Utibron Neohaler US8048451 Pharmaceutical compositions for inhalation Jun 27, 2021

(Expired)

Novartis
Utibron Neohaler US8303991 Method of making particles for use in a pharmaceutical composition Jun 27, 2021

(Expired)

Novartis
Utibron Neohaler US8435567 Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation Jun 27, 2021

(Expired)

Novartis
Utibron Neohaler US8580306 Particles for use in a pharmaceutical composition Jun 27, 2021

(Expired)

Novartis
Utibron Neohaler US8956661 Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof Jun 27, 2021

(Expired)

Novartis
Utibron Neohaler US9931304 Method of making particles for use in a pharmaceutical composition Jun 27, 2021

(Expired)

Novartis
Utibron Neohaler US9962338 Method of making particles for use in a pharmaceutical composition Jun 27, 2021

(Expired)

Novartis
Utibron Neohaler US7229607 Treatment of respiratory disease Apr 09, 2021

(Expired)

Novartis
Utibron Neohaler US8029768 Treatment of respiratory diseases Apr 09, 2021

(Expired)

Novartis
Utibron Neohaler US7820694 Beta-2-adrenoreceptor agonists Jun 02, 2020

(Expired)

Novartis
Utibron Neohaler US8067437 Beta-2-adrenoreceptor agonists Jun 02, 2020

(Expired)

Novartis
Utibron Neohaler US8283362 Beta-2-adrenoreceptor agonists Jun 02, 2020

(Expired)

Novartis
Utibron Neohaler US8658673 BETA2-adrenoreceptor agonists Jun 02, 2020

(Expired)

Novartis
Utibron Neohaler US8796307 Beta2-adrenoreceptor agonists Jun 02, 2020

(Expired)

Novartis
Utibron Neohaler US6582678 Carrier particles for use in dry powder inhalers Apr 24, 2018

(Expired)

Novartis
Utibron Neohaler US6521260 Carrier particles for use in dry powder inhalers Jan 31, 2016

(Expired)

Novartis



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Glycopyrrolate; Indacaterol Maleate's patents.

Given below is the list recent legal activities going on the following patents of Glycopyrrolate; Indacaterol Maleate.

Activity Date Patent Number
Patent litigations
Maintenance Fee Reminder Mailed 24 Jun, 2024 US8303991(Litigated)
Maintenance Fee Reminder Mailed 27 May, 2024 US8283362
Expire Patent 04 Dec, 2023 US8048451
Maintenance Fee Reminder Mailed 19 Jun, 2023 US8048451
Expire Patent 27 Mar, 2023 US8956661
Payment of Maintenance Fee, 12th Year, Large Entity 22 Mar, 2023 US8029768
Expire Patent 28 Nov, 2022 US7820694
Maintenance Fee Reminder Mailed 10 Oct, 2022 US8956661
Expire Patent 18 Jul, 2022 US7736670
Maintenance Fee Reminder Mailed 13 Jun, 2022 US7820694


Glycopyrrolate; Indacaterol Maleate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List